1. Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A review on iron chelators in treatment of iron overload syndromes. Int J Hematol Oncol Stem Cell Res. 2016;10(4):239–47.
2. Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol. 2016;6(1):1–19.
3. Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus Trasfus Sangue. 2012;10(4):411–22.
4. Botzenhardt S, Li N, Chan EW, Sing CW, Wong ICK, Neubert A. Safety profiles of iron chelators in young patients with haemoglobinopathies. Eur J Haematol. 2017;98(3):198–217.
5. Novartis. European Medicines Agency—Exjade Summary of Product Characteristics [Internet]. 2017 [cited 2017 Apr 24]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000670/human_med_000780.jsp&mid=WC0b01ac058001d124 .